Literature DB >> 7692672

Prevalence of anti-hepatitis C virus in the blood donor population of Rio de Janeiro.

B O Vanderborght1, A M Reis, C D Rouzere, R S da Silva, C F Yoshida, L G Franco, G Maertens, H Van Heuverswijn, J Moreira Pereira.   

Abstract

The prevalence of hepatitis C virus (HCV) antibodies in 2,557 asymptomatic volunteer Brazilian blood donors is reported. Using the line immunoassay (Inno-LIA) as a confirmatory test on ELISA anti-HCV-positive reacting sera, a prevalence rate of 2.7% for anti-HCV positivity was found. By comparison, prevalences of 1.6% for hepatitis B surface antigen, 0.9% for Treponema pallidum, 0.4% for human immunodeficiency virus and 0.04% for Trypanosoma cruzi were observed. Only 57% of the HCV-positive donors had elevated alanine aminotransferase (ALT) levels. Using previous criteria, based on surrogate markers (ALT > or = 50 IU/l and for anti-hepatitis B core antibody), for HCV infection at that time, only 25% of the HCV-positive donations would have been eliminated. In view of the high prevalence of anti-HCV reactivity among the Brazilian blood donor population and the poor reliability of surrogate markers, it is recommended that routine screening for anti-HCV in Brazilian blood donors is introduced.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692672     DOI: 10.1111/j.1423-0410.1993.tb02128.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  2 in total

1.  Risk factors for hepatitis C virus infection among blood donors in an HIV-epidemic area in Thailand.

Authors:  P Sawanpanyalert; S Boonmar; T Maeda; Y Matsuura; T Miyamura
Journal:  J Epidemiol Community Health       Date:  1996-04       Impact factor: 3.710

2.  Prevalence of second generation antibody to hepatitis C virus among voluntary blood donors in Osaka, Japan.

Authors:  H Tanaka; T Hiyama; H Tsukuma; Y Okubo; H Yamano; A Kitada; I Fujimoto
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.